Knowledge at the heart of leadership
Welcome to Liftstream - Life Sciences Executive Search and Leadership Advisory

BioNor Pharma impresses at 2014 AIDS conference

Authored by James Sheppard

The Oslo based biotech company BioNor Pharma recently announced the results of its REDUC trial. The topline results from part A of the trial demonstrated that the HDAX inhibitor (HIDACi) romidepsin is able to activate latent HIV reservoirs.

The trial combines BioNor’s vaccine candidate Vacc-4x with the cancer drug romidepsin. Romidepsin is also known as Istodax and is supplied by Celgene. BioNor announced the results of Part A of the trials which was designed to assess the safety and effect on HIV. The results showed that romidepsin successfully increased the virus production in HIV-infected cells between 2.1 and 3.9 times above normal. Of the 6 patients 5 showed the viral load had increased to measurable levels.

This approach to HIV treatment is known as ‘kick-kill.’ Firstly the virus is ‘kicked’ out of reservoirs making the HIV infected cells visable to the immune system. This should allow the immune response generated by Vacc-4x to attack and eliminate the infected cells.

Posted in Orphan Drugs and Rare Diseases, Pharmaceutical business | Tagged , , , , , , , , , , , , , , | Leave a comment

Contact Us

   Liftstream Ltd.
67 Grosvenor Street

   Tel: ​+44 (0)20 3178 5864

Register your CV

Apply for sector specific vacancies or request a confidential discussion

Registered in England No: 5009233
VAT: 843679292

Follow Us